Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Fusen Pharmaceutical Co Ltd

1652:HKG.HS

Fusen Pharmaceutical Co Ltd

Actions
  • Price (HKD)0.95
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-36.67%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fusen Pharmaceutical Co Ltd is a company mainly engaged in the cultivation of Chinese herbal medicine, pharmaceutical research and development, and sales. The Company's main business is the sales of Shuanghuanglian Oral Solutions, Shuanghuanglian Injections and other pharmaceutical products. The Company is also engaged in the research, production, and sales of various proprietary Chinese medicine and western medicine products for treating cold, fever, cardiovascular diseases and anemia. The Company mainly conducts business in the domestic market.

  • Revenue in HKD (TTM)464.65m
  • Net income in HKD-97.93m
  • Incorporated2013
  • Employees1.14k
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.